Microbial Cryptotopes are Prominent Targets of B-cell Immunity

Franz J. J. Rieder1, Julia Biebl1, Marie-Theres Kastner1, Martina Schneider2, Christof Jungbauer2, Monika Redlberger-Fritz3, William J. Britt4, Michael Kundi5 & Christoph Steininger1

B-cell recognition of microbial antigens may be limited by masking of epitopes within three-dimensional structures (cryptotopes). Here we report that unmasking of cryptotopes by unfolding whole cytomegalovirus (CMV) antigen preparations with the chaotropic reagent Urea and probing with immune sera from healthy individuals (n = 109) increased ELISA signals by 36% in comparison to folded CMV antigens (P < 0.001). ELISA signals increased also significantly upon unfolding of S. aureus or E. coli antigens, whereas unfolded influenza H1N1 or respiratory syncitial virus antigens yielded reduced or unchanged reactivity in comparison to folded ones, respectively. Blocking of CMV cryptotope-specific Abs by incubation of an immunoglobuline preparation and three sera with unfolded CMV antigens enhanced clearly the neutralizing capacity of this immunoglobuline preparation against CMV infection. Thus, B-cell immunity frequently targets cryptotopes on CMV but these Abs are non-neutralizing, may reduce the neutralizing effectiveness of pathogen-specific Abs, and increase during immune maturation following primary CMV infection. The observation of functional consequences of Abs specific for cryptotopes may open whole new avenues to a better understanding of the humoral immune response to CMV and development of more effective vaccines and immunoglobuline preparations.

The primary B-cell response to an antigen (Ag) triggers a cascade of adaptation events that provides the immune system with antibodies (Ab) of high affinity and specificity. Adaptation requires several months and involves multiple positive and negative selection processes1. The vast pre-immune B-cell repertoire undergoes a stochastic process of positive selection upon first encounter with a specific infectious pathogen. The expansion of B-cell reactivity provides the host with a repertoire that is collectively capable of recognizing a nearly limitless array of pathogen–specific Ag determinants with highly variable affinities for Ag2. The limits of B-cell diversity are determined by accessibility of targets on the 3-dimensional structure of polypeptide Ags for ligation with the B-cell receptor (BCR). Hence, virtually the entire accessible surface of a protein represents an antigenic continuum3.

Negative selection reduces pre-immune B-cell diversity by stringent scanning of BCRs for best available fit within a library of “imperfect” receptors to generate Ab of high specificity and affinity4,5. 

Multiple microbial defence mechanisms, however, may counteract these adaptation mechanisms and allow microbes to establish chronic or latent infections. For example, processing and presentation of antigens by the MHC class I pathway may be subverted by microbial proteins6. Microbes may encode homologs of cellular cytokines/chemokines and their receptors to modify the hosts’ immune response7. Posttranslational modifications of microbial polypeptides, such as extensive glycosylation, may mask antigenic structures and thereby delay or even inhibit maturation of pathogen-specific B-cell immunity8–10. 

Infectious pathogens may also counteract this process by masking potential immunological targets within their native three-dimensional structure (termed cryptic epitopes or cryptotopes)8–10. Cryptotopes may become immune targets occasionally upon protein unfolding11. Protein denaturation, proteolytic processing or presentation through Ag presenting cells (APCs) may expose hidden regions of a three-dimensional Ag to B-cell recognition12. Viral replication can involve structural plasticity of virions and temporal exposure of ostensibly

1Department of Medicine I, Div. of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria. 2Blood Donation Center of the Austrian Red Cross for Vienna, Lower Austria and Burgenland, Vienna, Austria. 3Department of Virology, Medical University of Vienna, Kinderspitalgasse 15, Vienna, Austria. 4Department of Pediatrics, Children’s Hospital, Birmingham, USA. 5Institute for Environmental Hygiene, Medical University of Vienna, Vienna, Austria. Correspondence and requests for materials should be addressed to C.S. (email: christoph.steininger@meduniwien.ac.at)
cryptotopes\(^{1,14}\). Ligation to receptors on target cells may expose B-cell epitopes such as ligation of the HIV envelope glycoprotein 120 (gp120) to the CD4 + receptor\(^{15}\).

B-cell recognition of exposed microbial cryptotopes may block infectivity in selected instances\(^{16}\). More commonly, however, cryptotopes induce a subdominant, low-affinity, non-neutralizing Ab response, which may even interfere with the function of neutralizing Abs\(^{17,18}\). Neutralizing hepatitis C virus (HCV)-specific Igs, for instance, may become ineffective by non-neutralizing HCV Abs targeting an adjacent cryptotope\(^{17}\). Cross-reactive, non-neutralizing Abs generated during a primary Dengue virus infection against cryptotopes were proposed to enhance the pathogenicity of subsequent infections via the process of antibody-dependent enhancement\(^{19}\). Furthermore, the immunological net effect of B-cell responses to multiple conformational, linear, and cryptic epitopes of complex infectious pathogens is largely unknown.

We hypothesized that B-cell responses to microbial cryptotopes are common and that interference of Abs to conformational and cryptic epitopes may result in incomplete microbial neutralization. For a thorough evaluation of the net effect of the B-cell response to cryptotopes, we studied first Ab reactivity to conformational and cryptic epitopes of CMV. The CMV genome codes for >180 gene products of which >30 reportedly trigger a B-cell response\(^{20}\). Next, we validated our findings at the example of other common viral and bacterial pathogens. Finally, the neutralizing capacity of antibodies to these different CMV epitope classes was evaluated in a neutralization assay. We found evidence that the B-cell response to CMV but not to other viral pathogens is highly skewed towards recognition of cryptotopes and that Abs to CMV cryptotopes interfere with the function of neutralizing antibodies. This observation has potentially far reaching implication in the diagnosis, prevention, and treatment of a wide array of infectious diseases.

Materials and Methods

Clinical samples and antibodies. Human serum samples were collected within a prospective cohort study at the Medical University of Vienna, Austria (cohort I) and the Red Cross Vienna, Austria (cohort II). Written informed consent was obtained from all patients at the time of enrolment. The study protocol was approved by the local institutional review board of the Medical University of Vienna in accordance with the Declaration of Helsinki (EK26/2012). Cohort I included healthy volunteers (n = 18) and patients with primary CMV infection (n = 20). The diagnosis of primary CMV infection was established by the presence of CMV-specific IgM and CMV-DNA in plasma and clinical signs and symptoms compatible with infectious mononucleosis. None of the patients had a history of immunodeficiency or an other underlying disease. The median interval between onset of CMV disease and blood collection was 25 days, mean age of these patients was 40 years. Cohort II included healthy blood donors (n = 150). The mean age of these blood donors was 54 years (SD, 11 years; range, 24 to 74 years) and 88% (132 of 150) of these donors were male.

Antigen preparations. The AD169 strain of CMV was propagated with the use of human foreskin fibroblasts (HFF), as previously described\(^{21}\). Cells were infected with CMV at a multiplicity of infection (MOI) of 0.01 and harvested as soon as a total cytopathogenic effect (CPE) developed. The propagation of the influenza A(H1N1)pdm09 strain was performed using MDCK-SIAT1 cells (HPA Culture Collection Cat.no. 05071502, passage number 6) according to standard procedures\(^{22}\). Respiratory syncitial virus (RSV) was propagated with the use of HeLa cells (ATCC® CCL2™, passage number 81) as described previously\(^{23}\).

Following collection of cell culture supernatant, residual cell debris was removed by centrifugation at 3000 × g for 30 min. Concentration and further purification of virions was achieved by high-speed centrifugation at 33,000 × g for 90 min. Viral pellets were resuspended in 1x Tris-buffered saline (TBS) (Bio-Rad, Hercules, CA, USA) containing 0.05% Tween-20 (TBS-T). To lyse virions, viral suspension samples were stored for 12 hours at 4 °C, sonicated, incubated again at 4 °C for 12 hours and stored at −20 °C\(^{24}\).

Escherichia coli (E. coli) strain JM109 was cultured in lysogeny broth (LB) for 12 hours at 37 °C. Staphylococcus aureus strain MRSA CCUG 26215 (agr1) (S. aureus) was cultured in Caso-Bouillon (Merck, Darmstadt, Germany) for 12 hours at 37 °C. To collect bacteria, samples were centrifuged (2500 × g, 30 minutes, 4 °C) and bacterial pellets resuspended in 1x TBS-T followed by sonication for disruption of the cell membrane.

The protein concentration of bacterial and viral lysates was measured with use of the Quick Start Bradford Protein Assay Kit (Bio-Rad, Hercules, CA, USA) or BCA Protein Assay (Thermo Scientific, Waltham, Massachusetts, USA) according to the manufacturer’s instructions. Bovine serum albumin (BSA) was used as reference protein for quantification, concentrations ranging from 2 mg/ml to 0.125 mg/ml (Bio-Rad, Hercules, CA, USA).

Recombinant expression of virus proteins. The open reading frames (ORFs) of CMV encoding the products of UL55 (glycoprotein B (gB)), UL32 (pp150 or pUL32), and UL83 (pp65) were cloned into the expression vector pCDNA 3.1. (Invitrogen Inc., Carlsbad, CA, USA). Human HEK293 cells were used for transient expression of all recombinant proteins following transfection using Lipofectamine 2000 (Invitrogen Inc., Carlsbad, CA, USA) according to the manufacturer’s recommendations. As a negative control, HEK293 cells were mock-transfected with the pCDNA 3.1. vector only. At 72 h post transfection, cells were harvested, washed with PBS and lysed by sonication. Subsequently, lysates were diluted in the appropriate buffer for enzyme-linked immunosorbent assay (ELISA).

SDS-PAGE and immunoblotting. Transfected HEK 293 cells were harvested 72 hours post transfection, washed with PBS and lysed in Tris-buffer by sonication. Following protein measurement (BCA Protein Assay), samples were diluted with Tris-buffer and 5x reducing sample buffer (300 mM, 1 M Tris, pH 6.8, 50% glycerol, 0.05% Bromophenol blue, 10% SDS and 10% 2-Mercaptoethanol) and boiled at 99 °C for 5 minutes. Subsequently, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed with use of 4–15%
gradient gels (Biorad, Hercules, CA, USA). After transfer to a PVDF membrane (#IPFL00010, Merck Millipore, Billerica, MA, USA), membranes were blocked with StartingBlock T20 (PBS) Blocking Buffer (Thermo Fisher Scientific, Waltham, MA, USA), incubated with an intravenous immunoglobulin preparations (IVIG), washed 3 times with PBS-T (0.05% Tween-20), incubated with anti-human secondary antibody (#sc2453, Santa Cruz, Dallas, TX, USA) and finally visualized using SuperSignal West Femto Chemiluminescent Substrate (Thermo Fisher Scientific, Waltham, MA, USA) and the ChemiDoc Imaging System (Biorad Inc., Hercules, CA, USA).

**Indirect ELISA.** Viral, bacterial, and HEK293 lysates were diluted in the appropriate coating buffer, incubated for 12 hours at 4 °C and processed thereafter as described for each experiment. The following buffers were used as coating buffers in our ELISA experiments: Tris buffer (50 mM Trizima-base, 150 mM NaCl, 5% Glycerol), Urea buffer (8 M Urea, 100 mM NaH2PO4, 10 mM Trizma Base), Guanidin buffer (100 mM NaH2PO4, 10 mM Tris-HCl, 6 M Guanidin HCl). For a more permanent denaturation of antigens, Tris-treated viral lysates were precipitated with use of TCA (Trichloroacetic acid) and Urea-treated lysates with ethanol (U-E). For this purpose, lysate were incubated in TCA (final concentration, 12%) for 20 minutes, centrifuged for 10 minutes at 7,000 × g, and pellets were subsequently washed with ice-cold acetone. Samples were then centrifuged for 10 minutes at 5,000 × g. acetone was removed and pellets air-dried to remove residual acetone. Alternatively, viral lysates were treated with Urea-buffer and then precipitated by incubation in 100% ethanol (U-E) for 1 hour at −20 °C followed by centrifugation for 10 minutes at 10,000 × g and removal of ethanol. Precipitates were resuspended in 1x Tris-buffered saline (TBS) and sonicated before use as antigen in the ELISA. All steps of the protein precipitation were done at 4 °C.

Microtiter plates (Corning Inc., Corning, NY, USA) were coated with clarified sonicates from viral or bacterial cultures, mock-transfected HEK293 cells or HEK293 cells transfected with vectors expressing either CMV gB, pUL32 or pp65 as described above. Following 12 hours of incubation at 4 °C, plates were washed four times with PBS with 0.05% Tween 20 (PBS-T) and then blocked with StartingBlock Blocking Buffer according to the manufacturer's instructions (Thermo Fisher Scientific Inc., Waltham, MA, USA). Plates were incubated overnight (O/N) at 4 °C with primary Ab preparation diluted in blocking buffer. After washing the plates four times with PBS-T, plates were incubated with mouse anti-human, IgG-specific, horseradish peroxidase (HRP)-labeled secondary Ab (#ab97160, Abcam, Cambridge, UK) at a final dilution of 1:10,000 for 2 hours at room temperature. For labelling of mouse primary Abs, goat anti-mouse IgG-specific, HRP-labeled Ab (cat. no. sc2005, Santa Cruz Biotechnology, Inc., Heidelberg, Germany) at a final dilution of 1:1,000 was used. After washing the plates again four times with PBS-T, plates were incubated with TMB Microwell Peroxidase Substrate System (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD, USA) for 20 minutes. The reaction was stopped with 1 M phosphoric acid and the optical density (OD) measured at a wavelength of 450 nm. Background signal was defined as mean OD without Ag.

To confirm equal amounts of protein adsorbed to ELISA plates despite the different treatment of antigen preparations, BSA was treated in parallel with Tris- or Urea-buffer and coated to the same ELISA plates as described for virus and cell lysates. Plates were washed thereafter four times with ddH2O instead of PBS-T to avoid interference of PBS-T with the silver staining solution used. Adsorbed proteins were visualized in the wells of the ELISA plates with use of a silver staining solution as described previously. In brief, 100 μl of silver staining solution was added per well and plates were incubated for 100 minutes at room temperature. Subsequently, OD was measured at 405 nm and not corrected for readings at 620 nm as recommended.

**Pre-adsorption of human sera for blocking neutralization assay.** Immune sera in form of intravenous immunoglobulin preparation (IVIG) were heat-inactivated at 56 °C for 30 minutes before blocking of specific Ab fractions with use of native or denatured protein preparations at RT for 1 hour followed by 4 °C O/N. For the preparation of blocking antigens, CMV virions were lysed either in Tris- or Urea-buffer by two freeze-thaw cycles, sonication and incubation at 4 °C for 24 hours. The Urea-treated lysate was ethanol precipitated and resuspended with Tris-buffer to enable reliable protein measurement and storage conditions.

**Blocking neutralization assay.** Evaluation of the neutralization capacity of human sera was done as described previously. Briefly, immune sera with and without blocking antigens were serially diluted in media (DMEM supplemented with 5% calf serum), mixed with CMV strain AD169 and incubated for 60 min at 37 °C. Following incubation, 0.1 ml of virus-Ab containing mixture was added to confluent primary human dermal fibroblasts in 96-well microtiter plates and incubated for 60 min at 37 °C. The monolayers were washed twice with media and then incubated overnight at 37 °C. The monolayers were washed with PBS and then fixed in 100% ethanol for 10 min on the following day. Following washing with PBS, the monolayers were incubated with anti-IE-1 monoclonal Ab (#sc-69834, Santa Cruz, Dallas, TX, USA) for 1 h and binding developed with a FITC goat anti-mouse IgG (#sc1010, Santa Cruz, Dallas, TX, USA). Fluorescent nuclei were counted using an epi-fluorescence microscope adapted for reading 96 well plates. Results were presented as percent of inhibition calculated from maximal infectivity in controls.

**Statistical Analysis.** Comparison of two groups was performed by use of the Mann-Whitney U test for quantitative parameters. Spearman-rho correlation coefficient was used to test for an association between non-normally distributed quantitative parameters. Dose-response curves from ELISA were assessed for parallelism by application of a four parameter logistic model. Fit was excellent with a pseudo R2 = 0.97. There was no significant deviation from parallelity and, therefore, relationship between preparations could be expressed as relative potency. Confidence intervals were computed based on Fieller's theorem. A P-value < 0.05 was considered as statistically significant. All statistical tests were done with use of the software package SPSS 22.0.
Results

CMV-specific ELISA signals are enhanced by unfolding of viral antigens. Unfolding of polypeptide Ags may compromise discontinuous, conformational epitopes, leave linear epitopes unaffected, and unmask cryptotopes. To evaluate the immunological net effect against CMV antigens, whole virus lysates were prepared under native and denaturing conditions and probed with immune sera from healthy individuals. First, proteins were chemically denatured with the chaotropic reagent Urea 8 M. ELISA signals obtained under these denaturing conditions were clearly higher than under native conditions and indicative for recruitment of additional, cryptotopes (Fig. 1A–D). The relative difference in signals was independent of the serum dilution used. For a uniform quantification of this difference in signals, we defined the cryptotope index (CI) in analogy to the avidity index. The CI is calculated as the ratio of the optical density (OD) under native conditions to the OD under denaturing conditions. A positive index number indicates a high proportion of IgG with reactivity to cryptotopes. To validate the observed increase in signals by Urea treatment of lysates, experiments were repeated with use of a further chaotropic denaturant, Guanidin 6 M (Fig. 1E). The CI measured under the influence of Urea or Guanidin were similarly high and all experiments yielded the same difference in signals under native and denaturing conditions (median CIUrea 0.36; SDUrea 0.18 vs. median CIGuanidin 0.31; SDGuanidin 0.39). To exclude that the differences in measured OD may be attributed to differences in adsorption of protein preparations to ELISA plates because of antigen treatment, BSA was treated in parallel with Tris or Urea, adsorbed to the same ELISA plates, and adsorbed proteins were quantified with use of a silver staining procedure (Fig. 1F). Protein concentrations in coating solutions of 2.5 μg/ml yielded clearly positive results and OD measurements did not differ significantly between these two protein preparations indicative of equal amounts of antigen bound to ELISA plates.

In addition, proteins were also denatured with use of Urea followed by ethanol-precipitation (U-E) or Tris-treated followed by TCA precipitation which reduces the propensity of protein refolding. Signals obtained under these denaturing conditions were clearly lower than under native conditions and indicative for a reduced availability of CMV-specific epitopes (Fig. 1E). Remarkably, the harsher denaturing treatment of TCA precipitation also yielded a more pronounced decrease in ELISA signals in comparison to ethanol precipitation.

Ab reactivity with CMV cryptotopes is associated with stage of infection. The B-cell response to CMV antigens exhibits considerable inter-host variability. To test whether this also holds true for reactivity with CMV cryptotopes, sera from a large cohort of unselected healthy blood donors (n = 150) were tested alike at a standard dilution (1:500) for CI. CMV-specific IgG were detectable in 73% (109 of 150) of the sera evaluated with use of the standard ELISA under native conditions. OD450 readings obtained under denaturing conditions correlated with those measured under native conditions (ρ = 0.95; P < 0.001 (Spearman-rho correlation coefficient)) and were overall clearly higher than those measured under native conditions (median CIUrea 0.36; IQR, 0.21–0.44; Fig. 2A). Neither age nor sex of the present blood donors was associated with CMV-specific CI (P = 0.536 and P = 0.767 (Mann-Whitney U)).

Optical density measured in ELISA is a three-parameter logistic function of Ig-concentration and may yield false positive results in sera with low Ab titres and vice versa. To evaluate whether concentration of CMV-specific Abs influences also CI, the CMV immune sera (n = 109) were tested in parallel at two further dilutions (1:1500 and 1:4500). This analysis showed that the CI measured at the standard dilution (1:500) correlated well with the CI measured at the 1:1500 and 1:4500 serum dilutions (P < 0.001, respectively (Spearman-rho correlation coefficient), Fig. 2B).

To evaluate whether CMV-specific CI is associated with the stage of CMV infection, sera from patients with primary CMV infection (n = 20) were also evaluated. Inter-host variability of CI was also low for samples from patients with primary CMV infection (median CI, 0.03; IQR, −0.02–0.07; Fig. 2A). Remarkably, the CI obtained with these samples was clearly lower in comparison to probing CMV lysates with immune sera from healthy blood donors indicative for a process of immune maturation (Fig. 2A).

Cryptotopes on individual CMV Ags. CMV whole virus lysate comprises a complex assortment of >30 B-cell Ags, which additionally harbour multiple conformational, linear, and very likely, cryptotopes. To elucidate the relative contribution of individual CMV antigens to the overall B-cell response to CMV cryptotopes, three of the most immunogenic CMV antigens (gB, pp65, pUL32) were evaluated also under native (Tris) and denaturing (Urea) conditions. Of the 16 sera from healthy controls, 11 reacted with all three antigens. The evaluation using these sera revealed positive CI for gB and pUL32 (median CI 0.66 and 0.71, respectively) and a clearly negative CI for pp65 (median CI = 3.94) (Fig. 3A,B). Western blot imaging confirmed expression of gB, pp65, and pUL32 by the transfected mammalian cells (Fig. 3C).

Ab reactivity with cryptotopes is associated with infectious pathogen. To test whether the variability in CI observed for the different CMV Ags reflects also differences between various human infectious pathogens, CI was determined also for reactivity of immune sera against two common bacterial and viral pathogens (Escherichia coli strain JM109, Staphylococcus aureus strain CCUG 26215, Influenza virus strain H1N1 and respiratory syncitial virus (RSV), respectively). Probing the bacterial Ag preparations with the immune sera under native and denaturing conditions yielded also positive CI (median CI E. coli: 0.190, S. aureus: 0.232) similarly to CMV whole virus lysate (median CI 0.36) (Fig. 4). In contrast, the CI measured for the influenza H1N1 was clearly negative (median CI = 0.819) and for RSV neutral (median CI = 0.024) which indicates a lower frequency of B-cells targeting cryptotopes than in CMV infection.

Functional consequences of Ab reactivity with cryptotopes. In order to evaluate the functional consequences of Ab ligation to CMV cryptotopes, we tested the neutralizing capacity of immune sera from one
patient with recent primary infection (serum 1) and two patients with latent infection (serum 2 & 3) and an immunoglobulin preparation (IVIG Baxter) with and without blocking of the different Ab fractions with use of native or unfolded CMV lysate (Fig. 5). IVIG are comprised of a complex amalgam of polyclonal Abs pooled from a large number of healthy plasma donors without modifications to the composition of Igs and therefore reflect the serostatus of the general population. All sera and the IVIG neutralized CMV in a dose-dependent manner (Fig. 5). Virus neutralization was higher with the sera from the latently infected individuals than from the recently infected one and the IVIG. Blocking of serum Abs with Urea-treated CMV lysate improved neutralization in all four serum preparations, whereas blocking with Tris-treated CMV lysate reduced the neutralization capacity.
Discussion

The B-cell response to infectious pathogens is directed against an array of conformational and linear epitopes on the exposed, three-dimensional structure of the microbe. The B-cell response to cryptotopes, however, may also...
be of high immunological relevance but did not receive much attention so far. Only a small number of cryptotopes have been identified so far on flaviviruses, HCV, HIV, Plasmodium falciparum, and influenza viruses. Our studies, however, indicate a high abundance of cryptotopes on selected viral and bacterial pathogen and an interference of this Ab fraction with neutralizing Ig. Recognition of B-cell responses to cryptotopes may have far reaching implications for the diagnosis, prevention and treatment of infectious diseases.

Urea potently denatures protein as a function of time, temperature and molarity. We used urea at 8 M to denature the presently evaluated whole microbial lysates and recombinant proteins. Nevertheless, refolding of proteins may occur rapidly upon removal of the denaturant urea and may be expected also in our experiments as plates were washed thoroughly with PBS-T before incubation with Abs to avoid interference of Urea with Ab binding. Still, we found clear differences in signals when using ELISA in different formats compatible with only partial refolding of Abs upon removal of the denaturants and conserved exposure of a large fraction of cryptotopes to ligation with specific Iggs. These observations indicate in concordance with previous studies that destabilization of folded protein structures is sufficient to expose cryptotopes. Moreover, refolding of denatured proteins may have been incomplete due to the hydrophobic polystyrene surfaces of ELISA plates used and folding and assembly of polypeptides in vivo requires other, chaperon proteins.

Hypothetically, treatment of proteins with denaturing reagents may change binding strength to ELISA plates in comparison to proteins coated under native conditions. To evaluate whether equal amounts of protein were adsorbed to ELISA plates, we quantified BSA adsorbed to ELISA plates after treatment with Tris- or Urea-buffer adsorbed under native (Tris) and denaturing (Urea) conditions. To evaluate whether equal amounts of protein were adsorbed to ELISA plates, we quantified BSA adsorbed to ELISA plates after treatment with Tris- or Urea-buffer adsorbed under native (Tris) and denaturing (Urea) conditions.

In viral infection, the most important function of Abs is neutralization of infectivity by binding to viral surface components and thereby interfering with functions that are essential for virus entry into cells. Cryptotope-specific Abs are assumed to be ineffective during most stages of viral replication and are mostly subdominant and non-neutralizing. Still, our observations indicate that (i) the healthy human immune system invests considerable resources into the B-cell response to CMV cryptotopes, (ii) the prominent B-cell response to cryptotopes separates CMV from infection with other viral pathogens, and (iii) the relative fraction of cryptotope-specific Abs appears to increase with time after primary infection. Taken together, it may speculated that skewing of CMV-specific B-cell immunity towards cryptotopes adds a further mechanism of CMV immune modulation and evasion to the already >100 mechanisms described so far.

Infectious pathogens commonly evade the immune response by hiding structures of importance for replication and infection, pUL32, for instance, is the large tegument protein of CMV, indispensable for CMV replication, hidden within the virion and still induces a strong, non-neutralizing B-cell response with an additional prominent targeting of cryptotopes. Partial disintegration of mature or immature viral and subviral particles, secretion of soluble forms of viral proteins from infected cells, release of incompletely processed and/or assembled viral proteins from lysed cells, as well as structural plasticity of virions may expose cryptotopes during the course of infection. Accumulation of such events during maturation of CMV-specific immunity may gradually shift the focus of B-cell immunity from neutralizing conformational to non-neutralizing cryptic epitopes and prolong Ab avidity maturation. On the other hand, pUL32-specific Abs are rarely boosted by CMV reactivation.
which is indicative for an infrequent presentation during reactivations from latency

Hence, the detection of cryptotope-specific Abs does not inevitably indicate biological or immunological significance for microbe or host. The net effect of Ab interactions measured in vitro may not necessarily be the same in vivo. For example, gB is the CMV antigen most commonly used in subunit vaccines because of a robust induction of neutralizing Igs. Multiple distinct B-cell epitopes were identified on gB that may induce neutralizing as well as non-neutralizing Abs. Our studies indicate the additional presence of gB cryptotopes that react with a large fraction of gB-specific Igs. The competition of neutralizing and non-neutralizing gB-specific Abs observed presently for whole CMV lysate or previously for HCMV stands in contrast to the protective B-cell immunity induced in a recent CMV vaccine trial with use of a full-length gB protein Ag. On the other hand, immunity induced with this gB vaccine was short-lived in concordance with our observed shift from targeting of conformational to cryptic epitopes during immune maturation. Selection of Ags according to propensity to induce a B-cell response to cryptotopes may improve significantly long-term efficacy of vaccines.

Treatment of patients with IVIG may prevent or mitigate a variety of infectious diseases (reviewed in ref. 46). IVIG are comprised of a complex amalgam of polyclonal Abs pooled from a large number of healthy plasma donors without modifications to the composition of Abs. The efficacy of CMV IVIG preparations used for the prevention of CMV infection or disease did not reach statistical significance in clinical trials. In contrast, measles virus, influenza virus or RSV infection may be efficiently prevented with use of IVIG preparations. Cryptotopes may be found on CMV as well as on influenza viruses. Our studies, however, indicate that Abs against CMV cryptotopes constitute a significantly larger fraction of virus-specific Ig in IVIG than those against influenza or RSV. Moreover, we could improve significantly the neutralizing capacity of sera and IVIG by blocking of Abs against CMV cryptotopes which apparently interfered with the function of neutralizing Igs. Apparently, Abs against cryptotopes may reduce the efficacy of IVIG in a dose-dependent manner and complete blocking of all CMV epitopes was not required to observe this effect as neutralization was not reduced significantly when using native CMV lysate for blocking. Although results have to be interpreted with caution in view of the limited number of samples tested and the use of only epithelial and not endothelial cells for viral propagation, removal of non-neutralizing fractions of CMV-specific Abs has the potential to improve clearly the effectiveness of IVIG in the prevention and treatment of CMV disease.

In conclusion, we identified a strong B-cell immune response to cryptotopes of CMV and other bacterial pathogens. The relative abundance of Ig fractions against cryptotopes increases with the maturation of immunity following primary CMV infection. The observation of functional consequences of Abs specific for cryptotopes may open whole new avenues to a better understanding of the humoral immune response and developing significantly more effective IVIG for the treatment of an array of infectious diseases.

**Figure 5.** Evaluation of neutralizing efficacy of immune sera from one patient with recent primary infection (serum 1) and two patients with latent infection (serum 2 & 3) and an immunoglobulin preparation (IVIG Baxter) after blocking of different fractions of CMV-specific Igs. Complement-inactivated sera and IVIG was either diluted with Tris-buffer (control) or pre-incubated with native whole CMV lysate (Tris) to block conformational and linear epitopes or unfolded whole CMV lysate (Urea-treated, precipitated with ethanol) to block preferentially cryptotopes. The horizontal, dashed line indicates 50% neutralization of virus. Final viral protein concentrations used for the IVIG experiment was 50 μg/ml and 5, 5 and 0.5 μg/ml for the experiments with the sera. Final dilution ranged from 1:100–1:800 as indicated in the figure. All experiments were done in triplicates and error bars indicate the standard error of the mean.
References

1. Nakra, P., Manivel, V., Vashwakarma, R. A. & Rao, K. V. B cell responses to a peptide epitope. X. Epitope selection in a primary response is thermodynamically regulated. J. Immunol. 164, 5615–5625 (2000).
2. Paige, C. J. & Wu, G. E. The B cell repertoire. Fascb. J. 3, 1818–1824 (1989).
3. Benjamin, D. C. et al. The antigenic structure of proteins: a reappraisal. Annu. Rev. Immunol. 2, 67–101 (1984).
4. Nayak, B. P. et al. B cell responses to a peptide epitope. V. Kinetic regulation of repertoire discrimination and antibody optimization for epitope. J. Immunol. 161, 3510–3519 (1998).
5. Tuteja, R. et al. B cell responses to a peptide epitope. II: Multiple levels of selection during maturation of primary responses. Immunol. Cell Biol. 75, 245–252 (1997).
6. Howcroft, T. K., Strebel, K., Martin, M. A. & Singer, D. S. Repression of MHC class I gene promoter activity by two-exon Tat of HIV. Science 260, 1320–1322 (1993).
7. McSharry, B. P., Avdiev, S. & Slobodman, B. Human cytomegalovirus encoded homologs of cytokines, chemokines and their receptors: roles in immunomodulation. Viruses. 4, 2448–2470 (2012).
8. Kropf, B. et al. Glycoprotein N of human cytomegalovirus protects the virus from neutralizing antibodies. Plos. Pathog. 8, e1002999 (2012).
9. Xu, R. et al. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 328, 357–360 (2010).
10. Steininger, C., Kundi, M., Kletzmayr, J., Aberle, S. W. & Popow-Kraupp, T. Antibody maturation and viremia after primary cytomegalovirus infection, in immunocompetent patients and kidney-transplant patients. J. Infect. Dis. 190, 1908–1912 (2004).
11. Pötzsch, S. et al. B cell repertoire analysis identifies new antigenic domains on glycoprotein b of human cytomegalovirus which are target of neutralizing antibodies. Plos Pathog. 7 (2011).
12. Brooks, P. C. et al. Ionizing radiation modulates the exposure of the HUIV26 cryptic epitope within collagen type IV during angiogenesis. Int. J. Radiat. Oncol. Biol. Phys. 54, 1194–1201 (2002).
13. Sabo, M. C. et al. Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature. Virology 422, 174–184 (2012).
14. Fabriansah, G. et al. Structural changes in dengue virus when exposed to a temperature of 37 degrees C. J. Virol. 87, 7585–7592 (2013).
15. Thal, M. et al. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67, 3978–3988 (1993).
16. Rathore, D. et al. An immunologically cryptic epitope of Plasmodium falciparum circumsporozoite protein facilitates liver cell recognition and induces protective antibodies that block liver cell invasion. J. Biol. Chem. 280, 20524–20529 (2005).
17. Zhang, P. et al. Hepatitis C virus epitope-specific neutralizing antibodies in IgG prepared from human plasma. Proc. Natl. Acad. Sci. USA 104, 8449–8454 (2007).
18. Ohmit, S. E. et al. Prevention of symptomatic seasonal influenza in 2005–2006 by inactivated and live attenuated vaccines. J. Infect. Dis. 198, 312–317 (2008).
19. Chan, A. H. et al. A human PrM antibody that recognizes a novel cryptic epitope on dengue E glycoprotein, 7, e33451 (2012).
20. Sylvestre, A. W. et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 202, 673–685 (2005).
21. Britt, W. J. Human cytomegalovirus: propagation, quantification, and storage. Curr. Protoc. Microbiol. Chapter 14, Unit (2010).
22. Nicholson, K. G., Wood, J. M. & Zambon, M. Influenza. Lancet 362, 1733–1745 (2003).
23. Lennette, E. H. & Schmidt, N. J. Diagnostic procedures for viral, rickettsial and chlamydial infections 5th ed. (American Public Health Association, Inc., Washington, D.C., 1979).
24. Vonka, V. & Benyesh-Melnick, M. Thermonaactivation of human cytomegalovirus. J. Bacteriol. 91, 221–226 (1966).
25. Root, D. D. & Wang, K. Kinetic silver staining and quantification of proteins adsorbed to microtiter plates. Anal. Biochem. 209, 354–359 (1993).
26. Boppiana, S. B., Polis, M. A., Kramer, A. A., Britt, W. J. & Koenig, S. Virus-specific antibody responses to human cytomegalovirus (HCMV) in human immunodeficiency virus type 1-infected persons with HCMV retinitis. J. Infect. Dis. 171, 182–185 (1995).
27. Andreoni, M., Faircloth, M., Vogler, L. & Britt, W. J. A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. J. Virol. Methods 23, 157–167 (1989).
28. Hua, L., Zhou, R., Thirumalai, D. & Berne, B. J. Urine denaturation by stronger dispersion interactions with proteins than water implies a 2-stage unfolding. Proc. Natl. Acad. Sci. USA 105, 16928–16933 (2008).
29. Xu, Z., Xie, Q. & Zhou, H. M. Trichloroacetic acid-induced molten globule state of aminoacylase from pig kidney. J. Protein Chem. 22, 669–675 (2003).
30. Beghetto, E. et al. Molecular dissection of the human B cell response against cytomegalovirus infection by lambda display. J. Virol. Methods 151, 7–14 (2008).
31. Eikert, D. C. et al. Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246–251 (2009).
32. Sui, J. et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct. Mol. Biol. 16, 265–273 (2009).
33. Stauan, K., Kiermayr, S., Holzmann, H. & Heinz, F. X. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J. Virol. 80, 9557–9568 (2006).
34. Zhu, L., Fan, Y. X. & Zhou, J. M. Identification of equilibrium and kinetic intermediates involved in folding of urea-denatured creatine kinase. Biochim. Biophys. Acta 1544, 320–332 (2001).
35. Loureiro, M. E. et al. Properties of cryptic epitopes and their corresponding antibodies as indicated by the study of human and ovine growth hormones. Immunol. Invest. 36, 159–174 (2007).
36. Gething, M. J. & Sambrook, J. Protein folding in the cell. Nature 355, 33–45 (1992).
37. Hangartner, L., Zinkernagel, R. M. & Hengartner, H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol. 6, 231–243 (2006).
38. Bengel, H., Brune, W. & Koszinowski, U. H. Immune evasion by cytomegalovirus–survival strategies of a highly adapted opportunist. Trends. Microbiol 6, 190–197 (1998).
39. Bou-Habib, D. C. et al. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J. Virol. 68, 6006–6013 (1994).
40. Sanchez, V., Greis, K. D., Sztul, E. & Britt, W. J. Accumulation of virion tegument and envelope proteins for anticytomegalovirus immunoglobulin M detection. J. Clin. Microbiol. 35, 393–397 (1997).
41. Vanura, K. et al. Chronic Lymphocytic Leukemia Patients Have a Preserved Cytomegalovirus-Specific Antibody Response despite Progressive Hypogammaglobulinemia. Plos. One. 8, e78925 (2013).
42. Speckner, A., Glykofydas, D., Ohlin, M. & Mach, M. Antigenic domain 1 of human cytomegalovirus glycoprotein B induces a multitude of different antibodies which, when combined, results in incomplete virus neutralization. J. Gen. Virol. 80, 2183–2191 (1999).
45. Pass, R. F. Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant. J. Clin. Virol. 46 Suppl 4, S73–S76 (2009).
46. Walker, S. P., Palma-Dias, R., Wood, E. M., Shekleton, P. & Giles, M. L. Cytomegalovirus in pregnancy: to screen or not to screen. BMC Pregnancy Childbirth. 13, 96 (2013).
47. Ranganathan, K. et al. Cytomegalovirus immunoglobulin decreases the risk of cytomegalovirus infection but not disease after pediatric lung transplantation. J. Heart Lung Transplant. 28, 1050–1056 (2009).
48. Snyderman, D. R. et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 119, 984–991 (1993).
49. Young, M. K., Nimmo, G. R., Cripps, A. W. & Jones, M. A. Post-exposure passive immunisation for preventing measles. Cochrane Database. Syst. Rev 4, CD010056 (2014).
50. Hung, I. F. et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 144, 464–473 (2013).
51. Groothuis, J. R., Hoopes, J. M. & Hemming, V. G. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis. Adv. Ther. 28, 110–125 (2011).

Acknowledgements
This study was supported by a research grant from the Austrian Science Fund P25353-B21.

Author Contributions
Conceptualization, C.S.; Methodology, C.S. and W.J.B.; Investigation, F.J.J.R., J.B., M.T.K., M.S., C.J., M.R.F., W.J.B. and M.K.; Writing – Original Draft, C.S. and F.J.J.R.; Writing – Review & Editing, C.S. and W.J.B.; Funding Acquisition, C.S. and W.J.B.; Resources, C.S. and W.J.B.

Additional Information
Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Rieder, F. J. J. et al. Microbial Cryptotopes are Prominent Targets of B-cell Immunity. Sci. Rep. 6, 31657; doi: 10.1038/srep31657 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016